CinnaGen Reports Results Of ReciGen For COVID-19
Iranian biotech CinnaGen Co. has unveiled positive results from the firm’s clinical studies trialing its ReciGen (interferon beta-1a) multiple-sclerosis as a treatment option to reduce COVID-19 symptoms.ReciGen, an immunomodulator ..... see more
Source : 'Generics Bulletin'
AdvaMed Expands VentConnect Platform To Bolster Medtech Supply Chain
Medical device industry trade group AdvaMed said on 3 August it’s expanding its successful VentConnect platform to support production of patient monitors, dialysis machines and diagnostic tests, among other equipment ..... see more
Source : Medtech Insight
How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
The government agency that develops medical countermeasures for the US stockpile says it had to move quickly to secure contract manufacturing plant capacity for ..... see more
Source : 'The Pink Sheet'
HHS Conditions Hospital COVID-19 Relief Payments On No Surprise Billing
The US Department of Health and Human Services is withholding government Provider Relief Funds from hospitals that hire out-of-network anesthesiologists, pathologists and radiologists who attempt to sock COVID-19 patients with ..... see more
Source : Medtech Insight
COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio
Growth in Baxter International Inc. acute therapies business continued in the second quarter of 2020, with the company reporting sales of $186m, a 40% increase, largely due to demand ..... see more
Source : Medtech Insight
UK Consortium Given Go-Ahead For Rapid SARS-CoV-2 Antibody Test In Europe
A rapid test for SARS-CoV-2 antibodies, developed by UK company Abingdon Health Ltd., has been CE-marked for professional use in the UK and EU. The company, which is ..... see more
Source : Medtech Insight
COVID-19: More Virtual Town Halls From FDA Through August
More virtual town halls are on the way from the US Food and Drug Administration that are aimed at labs and manufacturers that are (or have) developed diagnostic tests for ..... see more
Source : Medtech Insight
Coronavirus Update: Will Moderna Really Demand A Premium Price For Its COVID Vaccine?
Moderna is reported to be planning to price its COVID-19 vaccine at $50 to $60 per two-part treatment, a much higher level than indicated by other frontrunners.The Financial Times reported ..... see more
Source : 'Scrip Intelligence'
Moderna, Pfizer Protocols May Make COVID Vaccine Candidates Hard to Compare
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase III study designs, some vaccines experts said.“Both trials appeared to ..... see more
Source : 'The Pink Sheet'
Moderna’s COVID-19 Vaccine Price Will Be Test of US Negotiating Power
Reports that Moderna, Inc. is planning to price its COVID-19 vaccine at $50 to $60 per course is raising concern that the US may not get a ..... see more
Source : 'The Pink Sheet'
Kodak Establishes Pharmaceutical Unit To Tackle Shortages
The Eastman Kodak Company has announced successfully establishing its new business unit, Kodak Pharmaceuticals, which will produce critical pharmaceutical components that have been identified as essential but have lapsed into ..... see more
Source : 'Generics Bulletin'
European Industry Played Key Role In Mitigating COVID-19
The first half of 2020 has been defined by the outbreak of COVID-19. And with the coronavirus pandemic likely to continue to cast a long shadow, uncertainties within the off-patent ..... see more
Source : 'Generics Bulletin'
US FDA Highlights OTC Market With Template To Boost COVID-19 Test Development
Diagnostics companies working on tests for the novel coronavirus that could be distributed OTC got fresh guidance on 29 July as the US Food and Drug Administration published a template ..... see more
Source : 'HBW Insight'
Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines
Widespread dips in sales, particularly in Europe, after consumers stopped pandemic-driven stockpiling of OTC drugs and nutritional products, and the removal of OTC allergy Zantac in the US took big ..... see more
Source : 'HBW Insight'
China’s Coronavirus Vaccine Ambition Hampered By Lack Of Guidance On Overseas Clinical Data
As China’s state-owned Sinopharm Group Co. Ltd. starts its Phase III study in Abu Dhabi and Beijing-based Sinovac Biotech Ltd. commences its study with partner Butantan in Brazil, ..... see more
Source : 'The Pink Sheet'
FDA Boosts Development Of OTC COVID-19 Tests With New Template
Diagnostics companies working on tests for the novel coronavirus that could be distributed over the counter got fresh guidance on 29 July, as the US Food and Drug Administration released ..... see more
Source : Medtech Insight
Sanofi Forecasts Strong Flu Vaccine Growth, Accelerates COVID Plans
After seeing demand dry up for its vaccines portfolio during Q2 thanks to the pandemic, (down 6.8% to €927m), Sanofi is predicting a strong rebound in the second half ..... see more
Source : 'Scrip Intelligence'
